GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Candel Therapeutics Inc (NAS:CADL) » Definitions » Effective Interest Rate on Debt %

Candel Therapeutics (Candel Therapeutics) Effective Interest Rate on Debt % : 11.79% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Candel Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Candel Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $2.58 Mil. Candel Therapeutics's average total debt for the quarter that ended in Mar. 2024 was $21.92 Mil. Therefore, Candel Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 11.79%.


Candel Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Candel Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Candel Therapeutics Effective Interest Rate on Debt % Chart

Candel Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
- - 7.04 14.62 11.39

Candel Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.69 11.31 11.75 11.82 11.79

Competitive Comparison of Candel Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Candel Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Candel Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Candel Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Candel Therapeutics's Effective Interest Rate on Debt % falls into.



Candel Therapeutics Effective Interest Rate on Debt % Calculation

Candel Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -2.595/( (22.8+22.762)/ 2 )
=-1  *  -2.595/22.781
=11.39 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=22.336 + 0.464
=22.8

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=13.356 + 9.406
=22.762

Candel Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  -2.584/( (22.762+21.085)/ 2 )
=-1  *  -2.584/21.9235
=11.79 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=13.356 + 9.406
=22.762

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=10.792 + 10.293
=21.085

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Candel Therapeutics  (NAS:CADL) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Candel Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Candel Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Candel Therapeutics (Candel Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
117 Kendrick Street, Suite 450, Needham, MA, USA, 02494
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Executives
Nicoletta Loggia director CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM MA 02494
Jason Amello officer: Chief Financial Officer 500 KENDALL STREET, CAMBRIDGE MA 01824
Paul Peter Tak director, officer: President & CEO CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Christopher Martell director CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Seshu Tyagarajan officer: See Remarks CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Joseph C Papa director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Francesca Barone officer: Chief Scientific Officer CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
William Garrett Nichols officer: Chief Medical Officer C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Gary J. Nabel director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Renee Gaeta director C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Paul B Manning director 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Diem Nguyen director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Nathan Caffo officer: Chief Business Officer C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
John J Canepa officer: Chief Financial Officer 241 MATTINSON DRIVE, CONCORD MA 01742
Susan B. Stewart officer: Chief Regulatory Officer C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142